PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Clinical safety rating
safeNo significant drug interactions Can cause hypernatremia and fluid overload.
Proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells.
| Metabolism | Hepatic metabolism via CYP2C19 (major) and CYP3A4 (minor); metabolites include inactive desmethylpantoprazole and sulfone conjugates. |
| Excretion | Renal: approximately 80% as metabolites and unchanged drug; fecal: approximately 20% as metabolites. |
| Half-life | Approximately 1 hour (range 0.5–2 hours) in healthy adults; prolonged in hepatic impairment (up to 3–6 hours) and CYP2C19 poor metabolizers. |
| Protein binding | Approximately 98% bound to albumin. |
| Volume of Distribution | Approximately 0.15–0.26 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Intravenous: 100% (administered as infusion over 15 minutes); oral bioavailability is approximately 77% but this monograph pertains to IV formulation. |
| Onset of Action | Intravenous: inhibition of acid secretion begins within 15–30 minutes; maximal effect is achieved after 1–2 hours. |
| Duration of Action | Duration of acid suppression approximately 24 hours, allowing once-daily dosing; acid inhibition persists for several days after cessation due to irreversible binding to proton pumps. |
| Molecular Weight | 383.37 Da (pantoprazole sodium) |
40 mg intravenously over 2-15 minutes once daily for up to 10 days.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for renal impairment, including hemodialysis. |
| Liver impairment | In Child-Pugh Class A: no adjustment. In Child-Pugh Class B and C: maximum daily dose of 20 mg intravenously. |
| Pediatric use | For children ≥5 years: 15 kg to <40 kg: 20 mg once daily; ≥40 kg: 40 mg once daily. For children <5 years: safety and efficacy not established. |
| Geriatric use | No specific dose adjustment, but monitor for potential increased risk of adverse effects such as Clostridioides difficile infection and osteoporosis-related fractures. |
| 1st trimester | Limited human data; animal studies show no evidence of harm. Consider use only if clearly needed. |
| 2nd trimester | No known teratogenic risk; may be used if indicated. |
| 3rd trimester | Considered safe for short-term use; monitor for potential neonatal gastric pH effects. |
Clinical note
No significant drug interactions Can cause hypernatremia and fluid overload.
| FDA category | Animal |
| Placental transfer | Pantoprazole crosses the placenta in animal studies; human data limited but likely similar. |
| Breastfeeding | Pantoprazole is excreted into breast milk in low concentrations. No adverse effects observed in infants. Avoid if prolonged use or high doses. |
| Lactation Rating | L2 (Safe) |
| Teratogenic Risk | FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. First trimester: limited human data, no increased risk of major malformations. Second/third trimester: no known fetal risks. Risk of maternal hypomagnesemia with prolonged use may affect fetal bone development. |
| Fetal Monitoring | Monitor for maternal hypomagnesemia if prolonged therapy (>1 month); consider serum magnesium levels. No specific fetal monitoring required. |
| Fertility Effects | No evidence of impaired fertility in animal studies. Human data lacking; potential indirect effects via acid suppression not established. |
■ FDA Black Box Warning
None reported.
| Common Effects | Nausea Diarrhea Vomiting Stomach pain Flatulence Taste change Headache Rash |
| Serious Effects |
History of hypersensitivity to pantoprazole or any component of the formulationConcomitant use with rilpivirine
| Precautions | Prolonged use may increase risk of Clostridium difficile-associated diarrhea, Increased risk of osteoporosis-related fractures with long-term high-dose use, Hypomagnesemia reported with long-term use, Acute interstitial nephritis, May mask symptoms of gastric malignancy, Coadministration with methotrexate may increase methotrexate toxicity, Possible reduced absorption of vitamin B12 with long-term use |
| Food/Dietary | No significant food interactions with IV pantoprazole. However, if transitioning to oral therapy, advise taking oral pantoprazole at least 30 minutes before meals for maximal effect. Avoid alcohol as it can exacerbate gastric irritation and delay healing. |
| Clinical Pearls | Pantoprazole sodium in 0.9% sodium chloride is a proton pump inhibitor (PPI) for IV administration. Administer via IV infusion over 15-30 minutes; do not mix with other medications or IV solutions. Compatible with Y-site administration with selected drugs (e.g., cefepime, levofloxacin) per compatibility charts. Monitor for injection-site reactions, thrombophlebitis, and rare but serious side effects like acute interstitial nephritis, Clostridioides difficile infection, and hypomagnesemia with prolonged use. For stress ulcer prophylaxis in critically ill patients, IV pantoprazole is preferred over oral due to absorption concerns. Contraindicated in patients with known hypersensitivity to PPIs or substituted benzimidazoles. Dose adjustment not required in renal impairment but caution in hepatic impairment (max dose 40 mg/day in severe disease). Do not use for immediate symptom relief in acute dyspepsia as onset of action is delayed. |
| Patient Advice | This medication is given intravenously to reduce stomach acid; it is not used for immediate heartburn relief. · Inform your healthcare provider if you have liver disease, osteoporosis, or low magnesium levels. · Report any signs of allergic reaction (rash, difficulty breathing, swelling) or severe diarrhea (watery or bloody) immediately. · Long-term use may increase risk of bone fractures, especially in hip, wrist, or spine; discuss calcium and vitamin D supplementation. · Avoid alcohol and NSAIDs (ibuprofen, naproxen) as they can worsen stomach irritation. · Do not stop this medication abruptly without consulting your doctor, as acid rebound may occur. |
Loading safety data…